Finance

Lists
Why is DMYD-B up 2.19%?
Dive Deeper
DMYD-B:STO
Diamyd Medical AB
SEK 0.98
+2.19%
(+0.021) 1D
Oct 9, 5:29:56 PM GMT+2  ·   SEK
All symbols
SymbolPriceChange% Change
Generating top insights for DMYD-B...
Open
SEK 0.95
High
SEK 0.99
Low
SEK 0.92
Mkt. cap
148.45M
Avg. vol.
759.33K
Volume
894.92K
52-wk high
SEK 17.88
52-wk low
SEK 0.90
EPS
-SEK 1.98
Shares outstanding
134.00M
No. of employees
44
Open
SEK 0.95
High
SEK 0.99
Low
SEK 0.92
Mkt. cap
148.45M
Avg. vol.
759.33K
Volume
894.92K
52-wk high
SEK 17.88
52-wk low
SEK 0.90
EPS
-SEK 1.98
Shares outstanding
134.00M
No. of employees
44
News stories
From web sources and news partners
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products. The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB
CEOUlf Hannelius
Employees44
Founded1984
Headquarters-
SectorBiotechnology
Websitediamyd.com
Previous reportsAll values in SEK
Loading Previous Earnings...
Revenue
Net income
All values in SEK
Nov 2025
Feb 2026
May 2026
Aug 2026
Revenue
245.00K
99.00K
70.00K
1.42M
Cost of goods sold
938.00K
786.00K
964.00K
73.00K
Cost of revenue
938.00K
786.00K
964.00K
73.00K
Research and development expenses
30.47M
45.09M
105.01M
-439.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16.82M
18.30M
19.43M
16.28M
Operating expense
48.14M
64.34M
126.30M
17.86M
Total operating expenses
49.08M
65.12M
127.27M
17.94M
Operating income
-48.84M
-65.02M
-127.20M
-16.52M
Other non operating income
1.00K
1.00K
-
-1.00K
EBT including unusual items
-48.84M
-62.88M
-127.06M
-16.81M
EBT excluding unusual items
-48.06M
-62.88M
-127.06M
-16.68M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-925.00K
-840.00K
137.00K
295.00K
Net income
-48.84M
-62.88M
-127.06M
-16.81M
Net profit margin
-19,936.33%
-63,513.13%
-181,514.29%
-1,183.80%
Earnings per share
-
-
-
-
Interest and investment income
833.00K
2.78M
1.07M
1.74M
Interest expense
-62.00K
-635.00K
-930.00K
-1.90M
Net interest expenses
771.00K
2.14M
138.00K
-157.00K
Depreciation and amortization charges
1.78M
1.78M
1.73M
1.73M
EBITDA
-47.06M
-63.24M
-125.47M
-14.79M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps